Some insurers in the ACA’s small group market are citing tariffs, particularly those affecting prescriptions drugs, as a reason for higher-than-expected premium increases.
Recent Posts
- Distinguished Programs expands into reinsurance market with new Antares Re-backed platform
- Hyperscale data centres a growing but increasingly selective opportunity for re/insurers: S&P
- Lumos Insurance adds Kenny as MD & SVP, Global Retirement and Protection
- US flood landscape a strategic opportunity for incumbents and disruptors alike: Vardigans, Fathom
- Pacific Life Re completes third asset-intensive block reinsurance deal with Anshin Life